AXIM · CIK 0001514946
AXIM BIOTECHNOLOGIES, INC.
Annual figures as reported, FY2012–FY2023. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
$40K
▲ +345.3% vs FY2022
Net income
−$8.1M
▼ −29.1% vs FY2022
Free cash flow
−$1.0M
▲ +49.8% vs FY2022
Diluted EPS
−$0.04
▲ +0.0% vs FY2022
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersRevenue — Jun ’24 quarter
$17K
▲ +76.0% vs Jun ’23
Net income — Jun ’24 quarter
−$2.3M
▲ +39.0% vs Jun ’23
Revenue — trailing 12 months
$93K
▲ +253.6% vs Jun ’23
Diluted EPS — trailing 12 months
−$0.02
▲ +66.0% vs Jun ’23
Quarterly revenue
Discrete quarters; Q4 derived from the annual figure
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Jun ’24 | $17K | 76.0% | 90.0% | −$2.3M | −12986.0% | −$0.01 |
| Mar ’24 | $53K | 616.2% | — | −$292K | −551.7% | −$0.00 |
| Dec ’23 | $13K | 66.8% | — | −$1.9M | −15083.9% | −$0.01 |
| Sep ’23 | $10K | 629.1% | — | $328K | 3428.3% | $0.00 |
| Jun ’23 | $10K | — | 100.0% | −$3.7M | −37499.2% | −$0.02 |
| Mar ’23 | $7K | — | — | −$2.8M | −37348.0% | −$0.01 |
| Dec ’22 | $8K | 57.2% | — | −$899K | −11890.6% | −$0.01 |
| Sep ’22 | $1K | −83.8% | 100.0% | −$2.0M | −154836.1% | −$0.01 |
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Operating marginNet margin
Returns on capital
Net income vs year-end equity and assets
Cash flow
cash generationFree cash flow
Operating cash flow less capital expenditure
Operating cash flow
Net cash from operations
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Growth rates
compounding, annualizedRevenue CAGR
−27.4%
5y
+6.2%
10y
Key ratios
derived per fiscal year| Fiscal year | Op. margin | Net margin | FCF margin | ROE | ROA | Current ratio |
|---|---|---|---|---|---|---|
| FY2023 | −6961.0% | −20395.0% | −2607.7% | — | −195.5% | 0.03× |
| FY2022 | −52425.6% | −70343.1% | −23132.8% | — | −148.2% | 0.03× |
| FY2021 | −23114.5% | −26517.2% | −4180.1% | — | −301.2% | 0.25× |
| FY2020 | — | — | — | −409.4% | −56.7% | 0.48× |
| FY2019 | −388.9% | −806.5% | — | — | −381.1% | 0.48× |
| FY2018 | −2574.5% | −3453.0% | — | — | −323.3% | 0.61× |
| FY2017 | −6619.5% | −8761.7% | — | — | −190.1% | 0.27× |
| FY2016 | −7988.8% | −12346.0% | −2750.0% | — | −400.9% | 0.46× |
| FY2015 | −20451.3% | −20539.2% | −3098.1% | — | −800.0% | 0.46× |
| FY2014 | — | — | — | — | −78.9% | 0.56× |
| FY2013 | — | −411.8% | — | — | −157.0% | 0.02× |
| FY2012 | — | −34.4% | — | — | −11.2% | 0.28× |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2023 | $40K | — | −$2.8M | −$8.1M | −$0.04 | −$1.0M | $0 | $4.1M | $11.8M | −$7.7M | $156K | — |
| FY2022 | $9K | — | −$4.7M | −$6.2M | −$0.04 | −$2.0M | $9K | $4.2M | $9.0M | −$4.8M | $47K | — |
| FY2021 | $60K | — | −$14.0M | −$16.0M | $0.12 | −$2.5M | $40K | $5.3M | $7.7M | −$2.3M | $453K | — |
| FY2020 | $0 | — | −$4.9M | −$6.4M | −$0.06 | −$3.2M | $97K | $11.3M | $9.7M | $1.6M | $457K | — |
| FY2019 | $799K | — | −$3.1M | −$6.4M | −$0.10 | −$5.0M | — | $1.7M | $8.5M | −$6.8M | $512K | — |
| FY2018 | $196K | — | −$5.0M | −$6.8M | −$0.12 | −$4.8M | — | $2.1M | $8.2M | −$6.1M | $1.8M | — |
| FY2017 | $48K | — | −$3.1M | −$4.2M | −$0.08 | −$3.1M | — | $2.2M | $8.5M | −$6.3M | $2.1M | — |
| FY2016 | $47K | — | −$3.8M | −$5.8M | −$0.17 | −$1.3M | $0 | $1.4M | $3.8M | −$2.4M | $713K | — |
| FY2015 | $49K | — | −$10.0M | −$10.1M | −$0.27 | −$1.5M | −$17K | $1.3M | $3.0M | −$1.7M | $134K | — |
| FY2014 | $0 | — | −$506K | −$583K | −$0.02 | −$339K | $0 | $738K | $1.3M | −$581K | $661K | — |
| FY2013 | $22K | — | — | −$89K | $0.00 | −$33K | — | $57K | $151K | −$94K | $127 | — |
| FY2012 | $43K | — | — | −$15K | — | $21K | — | $133K | $138K | −$5K | $19K | — |
Latest filings
the most recent regulatory filings15-12GAXIM BIOTECHNOLOGIES, INC. FORM 15-12G2024-12-06 ↗NT 10-QAXIM BIOTECHNOLOGIES, INC._FORM NT 10-Q2024-11-13 ↗4PRIMARY DOCUMENT2024-10-15 ↗8-KAXIM BIOTECHNOLOGIES, INC. - FORM 8-K SEC FILING2024-10-15 ↗10-QQuarterly report2024-08-19 ↗NT 10-QAXIM BIOTECHNOLOGIES FORM 12B-252024-08-13 ↗10-Q/AQuarterly report2024-05-22 ↗10-QQuarterly report2024-05-20 ↗NT 10-QAXIM BIOTECHNOLOGIES FORM 12B-252024-05-15 ↗10-KAnnual report2024-04-16 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.